{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:evunzekibart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:prafnosbart [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:pimroctakin (bovine) [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04225039: Phase 2 Interventional Active, not recruiting Glioblastoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03352557: Phase 2 Interventional Terminated Alzheimer's Disease
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03262935: Phase 3 Interventional Completed Metastatic Breast Cancer
(2017)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:adintrevimab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:vensobafusp alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efparepoetin alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:bempikibart [INN]
Source URL:
Class:
PROTEIN
